A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Refractory/relapsed B cell lymphoma patients who received the available anti-CD19 chimeric antigen receptor (CAR) T cells may still experience a short duration of remission. Here in this study, we evaluated the safety and efficacy of a novel dominant-negative programmed cell death-1 (PD-1) armored a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Transl Oncol
Päätekijät: Liu, Xiaoqian, Zhang, Yuanfeng, Li, Kaimin, Liu, Yinghui, Xu, Junqing, Ma, Junjie, An, Licai, Wang, Hui, Chu, Xiaoxia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Neoplasia Press 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050776/
https://ncbi.nlm.nih.gov/pubmed/33813229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101085
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia